

**Amendments to the Claims:**

This listing of claims will replace all prior versions of the same numbered claims in the application:

Listing of claims:

33. (canceled) The composition comprising  $Mg^{2+}$  and at least one peptide which binds  $\alpha$ -synuclein and inhibits the aggregation thereof.

34. (canceled) The composition of claim 33, wherein the peptide binds the C-terminal or the NAC portion of  $\alpha$ -synuclein.

35. (currently amended) AThe composition comprising  $Mg^{2+}$  and at least one peptide of claim 34, wherein the peptide is selected from the group consisting of:  
WRQTRKD (SEQ ID NO: 1); HYAKNPI (SEQ ID NO: 2); ATINKSL (SEQ ID NO: 3); RRRGMAI (SEQ ID NO: 4); THRLPSR (SEQ ID NO: 5); TKHGPRK (SEQ ID NO: 6); SLKRLPK (SEQ ID NO: 7); RLRGRNQ (SEQ ID NO: 8); WPFHHHR (SEQ ID NO: 9); HLYHHKT (SEQ ID NO: 10); THIHHP (SEQ ID NO: 11); and MMMMMRL (SEQ ID NO: 12).

36. (previously amended) The composition of claim 35, wherein the peptide is selected from the group consisting of: THRLPSR (SEQ ID NO: 5); SLKRLPK (SEQ ID NO: 7); THIHHP (SEQ ID NO: 11); and MMMMMRL (SEQ ID NO: 12).

37. (previously amended) The composition of claim 36, wherein the peptide is SLKRLPK (SEQ ID NO: 7).

38. (currently amended) The composition of claim 35, wherein  $Mg^{2+}$  is  $MgSO_4$ .